BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20842105)

  • 1. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
    Samuel S; Tumilasci VF; Oliere S; Nguyên TL; Shamy A; Bell J; Hiscott J
    Mol Ther; 2010 Dec; 18(12):2094-103. PubMed ID: 20842105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
    Tumilasci VF; Olière S; Nguyên TL; Shamy A; Bell J; Hiscott J
    J Virol; 2008 Sep; 82(17):8487-99. PubMed ID: 18579592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
    Samuel S; Beljanski V; Van Grevenynghe J; Richards S; Ben Yebdri F; He Z; Nichols C; Belgnaoui SM; Steel C; Goulet ML; Shamy A; Brown D; Abesada G; Haddad EK; Hiscott J
    Mol Ther; 2013 Jul; 21(7):1413-23. PubMed ID: 23689597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
    Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Okumura K; Sinicrope FA
    Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL.
    Pearce AF; Lyles DS
    J Virol; 2009 Sep; 83(18):9102-12. PubMed ID: 19587033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
    Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
    Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
    Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
    Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.
    Schache P; Gürlevik E; Strüver N; Woller N; Malek N; Zender L; Manns M; Wirth T; Kühnel F; Kubicka S
    Gene Ther; 2009 Jul; 16(7):849-61. PubMed ID: 19369968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy.
    Heidari N; Hicks MA; Harada H
    Cell Death Dis; 2010 Sep; 1(9):e76. PubMed ID: 21364679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM; Claxton DF; Crump M; Faderl S; Kipps T; Keating MJ; Viallet J; Cheson BD
    Blood; 2009 Jan; 113(2):299-305. PubMed ID: 18931344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
    McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
    Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.